Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.70 |
| ▸ | DRD4 | P21917 | 1/20 | 0.70 |
| ▸ | DRD3 | P35462 | 1/20 | 0.70 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.56 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.53 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.52 |
| ▸ | CDK7 | P50613 | 1/20 | 0.52 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | PDE2A | O00408 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.46 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.45 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31010088 | 0.84 | DRD2 (0.54) | DRD2DRD4DRD3CHEK1CDK7 | |
| SCHEMBL25658283 | 0.82 | DRD4 (1.00) | DRD2DRD4DRD3ALDH1A1KDM4E | |
| SCHEMBL28331995 | 0.79 | HRH3 (0.57) | DRD2DRD4DRD3HRH3HRH4 | |
| SCHEMBL6097276 | 0.78 | HRH3 (0.57) | DRD2DRD4DRD3HRH3CHEK1 | |
| SCHEMBL28181607 | 0.77 | NOTUM (0.59) | DRD2DRD4DRD3NOTUMALDH1A1 | |
| SCHEMBL23389916 | 0.76 | DRD2 (0.59) | DRD2DRD4DRD3NOTUMCHEK1 | |
| SCHEMBL711055 | 0.76 | NOTUM (0.63) | DRD2DRD4DRD3NOTUMALDH1A1 | |
| SCHEMBL13737026 | 0.76 | CHRNA7 (0.60) | DRD2DRD4DRD3HRH3NOTUM | |
| SCHEMBL597565 | 0.76 | PSMB1 (0.55) | HRH3CHRNB2CHRNA4 | |
| SCHEMBL30363993 | 0.76 | GAA (0.55) | DRD2DRD4DRD3HRH3HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240245670-A1 | DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | NOVARTIS AG (CH) | 2024-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240245670-A1 | DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | IKZF1, IKZF2, IKZF3 | DRD2 3504/4885DRD4 3620/4885DRD3 4024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.